Euro
USD
British Pound
NULL
Product Description
Brivanib is a potent, ATP-competitive inhibitor against human Flk-1 (VEGFR-2) and mouse Flk-1 with IC₅₀ of 25 nM and 89 nM, respectively. Brivanib also inhibits VEGFR-1 and FGFR-1 with IC₅₀ values of 0.38 and 0.148 μM. Brivanib displays antitumor activities in H3396 xenograft.
Brivanib is a potent, ATP-competitive inhibitor against human Flk-1 (VEGFR-2) and mouse Flk-1 with IC₅₀ of 25 nM and 89 nM, respectively. Brivanib also inhibits VEGFR-1 and FGFR-1 with IC₅₀ values of 0.38 and 0.148 μM. Brivanib displays antitumor activities in H3396 xenograft.
Biovision | B1325 | Brivanib DataSheet
Alternate Name/Synonyms: (R)-1-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy)propan-2-ol; BMS-540215
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 649735-46-6
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₉H₁₉FN₄O₃
Molecular Weight: 370.38
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (>30 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent, ATP-competitive inhibitor against human Flk-1 (VEGFR-2) and mouse Flk-1
MDL Number: N/A
PubChem CID: 11234052
SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C
InChi: InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
InChi Key: WCWUXEGQKLTGDX-LLVKDONJSA-N
